Ultrasound-mediated transscleral delivery of macromolecules to the posterior segment of rabbit eye in vivo

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 6, 2013, Pages 4358-4365

  Suen, Wai Leung Langston ^a   Wong, Hoi Sang ^a   Yu, Yu ^a   Lau, Laurence Chi Ming ^b   Lo, Amy Cheuk Yin ^b   Chau, Ying ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Needleless; Noninvasive; Ocular delivery; Retinal disease

Indexed keywords

DEXTRAN;

AMPLIFIER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG PENETRATION; ECHOOCULOGRAPHY; ELECTRORETINOGRAPHY; FLUORESCENCE ANALYSIS; GENERATOR; HISTOLOGY; IN VIVO STUDY; MACROMOLECULE; NON INVASIVE PROCEDURE; NONHUMAN; OPHTHALMOSCOPY; OSCILLOSCOPE; POSTERIOR EYE SEGMENT; PRIORITY JOURNAL; RABBIT; RETINA DISEASE; SCLERA; TISSUE STRUCTURE; ULTRASOUND TRANSDUCER; VISUAL SYSTEM FUNCTION;

NEEDLELESS; NONINVASIVE; OCULAR DELIVERY; RETINAL DISEASE;

ANIMALS; DEXTRANS; DRUG DELIVERY SYSTEMS; ELECTRORETINOGRAPHY; FLUORESCENCE; IONTOPHORESIS; MACROMOLECULAR SUBSTANCES; OPHTHALMOSCOPY; POSTERIOR EYE SEGMENT; RABBITS; RETINAL DISEASES; SCLERA; ULTRASONICS; VITREOUS BODY;

EID: 84879598420     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-11978     Document Type: Article

References (46)

1. World Health Organization. Prevention of blindness and visual impairment: Priority eye diseases-Age related macular degeneration. Available at: http://www.who.int/blindness/causes/priority/en/index8.html. Accessed January 20, 2013
2. Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother. 2012;13:585-591
3. Moshfeghi AA, Puliafito CA. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2005;14:671-682
4. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Current Opin Ophthalmol. 2010;21:218-226
5. Schmucker C, Loke YK, Ehlken C, et al. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol. 2011;95:308-317
6. Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108:6241-6245
7. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41:1181-1185
8. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003;87:24-27
9. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81-87
10. Sonmez K, Ozturk F. Complications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevation. Int J Ophthalmol. 2012;5:719-725
11. D.M. Maurice SM. Ocular pharmacokinetics. Pharmacol Eye. 1984;69:19-116
12. Barza M. Antibacterial agents in the treatment of ocular infections. Infect Dis Clin North Am. 1989;3:533-551
13. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv. 2004;1:99-114
14. Ranta VP, Urtti A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev. 2006;58:1164-1181
15. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Advanced Drug Deliv Rev. 2001; 52:37-48
16. Lee SJ, He W, Robinson SB, Robinson MR, Csaky KG, Kim H. Evaluation of clearance mechanisms with transscleral drug delivery. Invest Ophthalmol Vis Sci. 2010;51:5205-5212
17. Paganelli F, Cardillo JA, Dare AR, et al. Controlled transscleral drug delivery formulations to the eye: establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis. Expert Opin Drug Deliv. 2010;7:955-965
18. Watson PG, Young RD. Scleral structure, organisation and disease. A review. Exp Eye Res. 2004;78:609-623
19. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87:1479-1488
20. Cheung AC, Yu Y, Tay D, Wong HS, Ellis-Behnke R, Chau Y. Ultrasound-enhanced intrascleral delivery of protein. Int J Pharm. 2010;401:16-24
21. Chau Y. Enhancement of transscleral transport of macromolecules by sonophoresis. Presented at: 38th Annual Meeting & Exposition of the Controlled Release Society; August 2011; National Harbor, MD.
22. Wong H-S. Ultrasound-Mediated Transscleral Drug Delivery. Hong Kong, China: Department of Chemical and Biomolecular Engineering: The Hong Kong University of Science and Technology. 2011;89
23. Zderic V, Vaezy S, Martin RW, Clark JI. Ocular drug delivery using 20-kHz ultrasound. Ultrasound Med Biol. 2002;28:823-829
24. Szabo TL. Diagnostic Ultrasound Imaging: Inside Out. Waltham: Academic Press; 2004:576
25. Enea NA, Hollis TM, Kern JA, Gardner TW. Histamine H1 receptors mediate increased blood-retinal barrier permeability in experimental diabetes. Arch Ophthalmol. 1989;107:270-274
26. Kim SH, Lutz RJ, Wang NS, Robinson MR. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res. 2007;39:244-254
27. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-2548
28. Shuler RK Jr, Dioguardi PK, Henjy C, Nickerson JM, Cruysberg LP, Edelhauser HF. Scleral permeability of a small, singlestranded oligonucleotide. J Ocul Pharmacol Ther. 2004;20: 159-168
29. Ottiger M, Thiel MA, Feige U, Lichtlen P, Urech DM. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci. 2009;50: 779-786
30. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007;27:1260-1266
31. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146:508-512
32. Chau Y, Tse HY. Investigation of the mechanism of ultrasoundenhanced transscleral transport of macromolecules. Presented at: 2011 American Institute of Chemical Engineers Annual Meeting; October 2011; Minneapolis, MN.
33. Tang H, Blankschtein D, Langer R. Effects of low-frequency ultrasound on the transdermal permeation of mannitol: comparative studies with in vivo and in vitro skin. J Pharm Sci. 2002;91:1776-1794
34. Tezel A, Mitragotri S. Interactions of inertial cavitation bubbles with stratum corneum lipid bilayers during low-frequency sonophoresis. Biophys J. 2003;85:3502-3512
35. Park EJ, Zhang YZ, Vykhodtseva N, McDannold N. Ultrasoundmediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. J Control Release. 2012;163:277-284
36. Husseini GA, Pitt WG. Ultrasonic-activated micellar drug delivery for cancer treatment. J Pharm Sci. 2009;98:795-811
37. Schroeder A, Honen R, Turjeman K, Gabizon A, Kost J, Barenholz Y. Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release. 2009;137:63-68
38. O'Brien WD. Ultrasound-biophysics mechanisms. Prog Biophys Mol Bio. 2007;93:212-255
39. Bigelow TA, Church CC, Sandstrom K, et al. The thermal index: its strengths, weaknesses, and proposed improvements. J Ultrasound Med. 2011;30:714-734
40. Gomez-Ulla F, Basauri E, Arias L, Martinez-Sanz F. Management of intravitreal injections. Arch Soc Esp Oftalmol. 2009;84:377-388
41. Brown KT. The electroretinogram: its components and their origin. Vision Res. 1968;8:633-777
42. Brown KT, Murakami MA. New receptor potential of the monkey retina with no detectable latency. Nature. 1964;201: 626-628
43. Brown KT, Wiesel TN. Analysis of the intraretinal electroretinogram in the intact cat eye. J Physiol. 1961;158:229-256
44. Dick E, Miller RF, Bloomfield S. Extracellular Kth activity changes related to electroretinogram components. II. Rabbit (E-type) retinas. J Gen Physiol. 1985;85:911-931
45. Choudhury BP. Ganglion cell distribution in the albino rabbit's retina. Exp Neurol. 1981;72:638-644
46. Oyster CW, Takahashi ES, Hurst DC. Density, soma size, and regional distribution of rabbit retinal ganglion cells. J Neurosci. 1981;1:1331-1346.